$WDDD
Worlds Inc Stock $wddd

$wddd Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000126493123000006 Filed on March 31, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue		$0.00
YoY Change
Cost Of Revenue		$0.00
YoY Change
Gross Profit		$0.00
YoY Change
Gross Profit Margin
Selling, General & Admin	$25.72K	$924.8K	$1.298M
YoY Change	-91.02%	649.79%	-26.07%
% of Gross Profit
Research & Development	$0.00
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$11.57K	$924.8K	$1.298M
YoY Change	-95.96%	649.79%	-26.07%
Operating Profit	-$79.83K	-$924.8K	-$1.504M
YoY Change	-72.14%	649.79%	-14.34%
Interest Expense	$18.71K	$843.0K	$75.88K
YoY Change	-104.13%	-5520.9%	-90.82%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$29.51K	-$331.1K	-$1.035M
YoY Change	-96.01%	138.38%	68.59%
Income Tax
% Of Pretax Income
Net Earnings	-$29.51K	-$331.1K	-$1.035M
YoY Change	-96.01%	138.38%	68.59%
Net Earnings / Revenue
Basic Earnings Per Share	$0.00		-$0.02
Diluted Earnings Per Share	$0.00	-$0.01	-$0.02
COMMON SHARES
Basic Shares Outstanding	57.11M shares	57.11M shares	57.11M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$80.68K	$7.780K	$7.780K
YoY Change	25.65%	-82.49%	-82.49%
Cash & Equivalents	$80.68K	$7.778K	$7.780K
Short-Term Investments
Other Short-Term Assets			$0.00
YoY Change			-100.0%
Inventory
Prepaid Expenses		$0.00
Receivables
Other Receivables
Total Short-Term Assets	$80.68K	$7.778K	$7.780K
YoY Change	11.38%	-85.23%	-85.22%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
TOTAL ASSETS
Total Short-Term Assets	$80.68K	$7.778K	$7.780K
Total Long-Term Assets	$0.00	$0.00	$0.00
Total Assets	$80.68K	$7.778K	$7.780K
YoY Change	-73.75%	-97.26%	-97.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$800.4K	$797.9K	$797.9K
YoY Change	-11.48%	-18.18%	-18.18%
Accrued Expenses	$1.716M	$1.661M	$1.661M
YoY Change	10.24%	7.4%	7.4%
Deferred Revenue
YoY Change
Short-Term Debt	$773.3K	$773.3K	$773.3K
YoY Change	0.0%	0.0%	0.0%
Long-Term Debt Due	$45.00K
YoY Change
Total Short-Term Liabilities	$3.335M	$3.232M	$3.232M
YoY Change	3.11%	-1.91%	-1.91%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.335M	$3.232M	$3.232M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$3.335M	$3.232M	$3.232M
YoY Change	3.11%	-1.91%	-1.91%
SHAREHOLDERS EQUITY
Retained Earnings	$46.85M	$46.82M
YoY Change		-202.26%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$3.254M	-$3.224M	-$3.224M
YoY Change
Total Liabilities & Shareholders Equity	$80.68K	$7.778K	$7.780K
YoY Change	-73.75%	-97.26%	-97.26%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$29.51K	-$331.1K	-$1.035M
YoY Change	-96.01%	138.38%	68.59%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$41.14K	-$111.5K	-$830.0K
YoY Change	-88.04%	-62.1%	-41.65%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$69.04K	$793.4K	$793.4K
YoY Change	-81.03%	-20.05%	-20.05%
Cash From Investing Activities	$69.04K	$793.4K	$793.4K
YoY Change	-81.03%	-20.05%	-20.05%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$45.00K
YoY Change
NET CHANGE
Cash From Operating Activities	-$41.14K	-111.5K	-$830.0K
Cash From Investing Activities	$69.04K	793.4K	$793.4K
Cash From Financing Activities	$45.00K
Net Change In Cash	$72.90K	681.9K	-$36.64K
YoY Change	268.35%	-2.33%	-91.48%
FREE CASH FLOW
Cash From Operating Activities	-$41.14K	-$111.5K	-$830.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	1713375	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	57112506	shares
CY2022	dei	Auditor Name AuditorName	M&K CPAS, PLLC
CY2022	dei	Auditor Firm AuditorFirmId	2738
CY2021	us-gaap	Gross Profit GrossProfit		usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2021	us-gaap	Other Comprehensive Income Availableforsale Securities Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToNoncontrollingInterest		usd
CY2022	WDDD	Loss On Issuance Of Shares For Services LossOnIssuanceOfSharesForServices		usd
CY2022	us-gaap	Litigation Settlement Amount Awarded From Other Party LitigationSettlementAmountAwardedFromOtherParty		usd
CY2021	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement		usd
CY2022	us-gaap	Interest Income Operating InterestIncomeOperating		usd
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt		usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties		usd
CY2021	us-gaap	Certain Loans Acquired In Transfer Accounted For As Debt Securities Otherthan Temporary Impairment Charges Credit Loss CertainLoansAcquiredInTransferAccountedForAsDebtSecuritiesOtherthanTemporaryImpairmentChargesCreditLoss		usd
CY2021	us-gaap	Litigation Settlement Expense LitigationSettlementExpense		usd
CY2022	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet		usd
CY2022	us-gaap	Stock Issued1 StockIssued1		usd
CY2022	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness		usd
CY2022	us-gaap	Interest Paid InterestPaid		usd
CY2021	us-gaap	Interest Paid InterestPaid		usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2022	WDDD	Patent Number Nine PatentNumberNine	8640028	interger
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0000001961
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent		usd
CY2022Q4	us-gaap	Notes Receivable Net NotesReceivableNet		usd
CY2022Q4	us-gaap	Interest Receivable InterestReceivable		usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue		usd
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	000-24115
CY2022	dei	Entity Registrant Name EntityRegistrantName	WORLDS INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	22-1848316
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	11 Royal Road
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Brookline
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02445
CY2022	dei	City Area Code CityAreaCode	(617)
CY2022	dei	Local Phone Number LocalPhoneNumber	725-8900
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Auditor Location AuditorLocation	Houston, TX
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7778	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	44421	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	8222	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	7778	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	52643	usd
CY2021Q4	us-gaap	Notes Receivable Net NotesReceivableNet	200000	usd
CY2021Q4	us-gaap	Interest Receivable InterestReceivable	31461	usd
CY2022Q4	us-gaap	Assets Assets	7778	usd
CY2021Q4	us-gaap	Assets Assets	284104	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	797908	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	975255	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1660933	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1546480	usd
CY2022Q4	us-gaap	Notes And Loans Payable NotesAndLoansPayable	773279	usd
CY2021Q4	us-gaap	Notes And Loans Payable NotesAndLoansPayable	773279	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3232120	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3295014	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3232120	usd
CY2021Q4	us-gaap	Liabilities Liabilities	3295014	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57112506	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57112506	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	57112506	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	57112506	shares
CY2022Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	57113	usd
CY2021Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	57113	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	42335725	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	41513730	usd
CY2022Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1206913	usd
CY2021Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1206913	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	46824093	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	45788666	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3224342	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-3010910	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7778	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	284104	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1297681	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1649872	usd
CY2022	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	206013	usd
CY2021	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	215332	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-1503693	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-1865204	usd
CY2022	us-gaap	Other Comprehensive Income Availableforsale Securities Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToNoncontrollingInterest	-231462	usd
CY2021	WDDD	Loss On Issuance Of Shares For Services LossOnIssuanceOfSharesForServices	8685	usd
CY2022	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	793391	usd
CY2021	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	1006588	usd
CY2021	us-gaap	Litigation Settlement Amount Awarded From Other Party LitigationSettlementAmountAwardedFromOtherParty	315000	usd
CY2022	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	17780	usd
CY2021	us-gaap	Interest Income Operating InterestIncomeOperating	14194	usd
CY2022	us-gaap	Interest Expense InterestExpense	75883	usd
CY2021	us-gaap	Interest Expense InterestExpense	76063	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-1035427	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-614170	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57112506	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57072544	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-2669888	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised Net Of Tax Benefit Expense StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense	109874	usd
CY2021	WDDD	Common Stock Issued For Settlement Of Accounts Payable Related Party1 CommonStockIssuedForSettlementOfAccountsPayableRelatedParty1	70810	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	16401	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	76063	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-614170	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-3010910	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised Net Of Tax Benefit Expense StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense	821995	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-1035427	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3224342	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-1035427	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-614170	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	821995	usd
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	109874	usd
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	76063	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	8685	usd
CY2022	us-gaap	Certain Loans Acquired In Transfer Accounted For As Debt Securities Otherthan Temporary Impairment Charges Credit Loss CertainLoansAcquiredInTransferAccountedForAsDebtSecuritiesOtherthanTemporaryImpairmentChargesCreditLoss	231462	usd
CY2022	us-gaap	Increase Decrease In Marketable Securities Restricted IncreaseDecreaseInMarketableSecuritiesRestricted	-793391	usd
CY2021	us-gaap	Increase Decrease In Marketable Securities Restricted IncreaseDecreaseInMarketableSecuritiesRestricted	-1006588	usd
CY2022	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	17780	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	8222	usd
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-8222	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-62894	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	11798	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-830034	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1422560	usd
CY2021	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-14194	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	793391	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1006588	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	793391	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	992394	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-36643	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-430166	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	44421	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	474587	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7778	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	44421	usd
CY2021	us-gaap	Stock Issued1 StockIssued1	62125	usd
CY2021	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	14401	usd
CY2022	WDDD	Working Capital Deficiency Going Concern WorkingCapitalDeficiencyGoingConcern	3148459	usd
CY2022	WDDD	Stockholders Deficiency Going Concern StockholdersDeficiencyGoingConcern	3148459	usd
CY2022	WDDD	Cash In Operations Going Concern CashInOperationsGoingConcern	830034	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_844_eus-gaap--UseOfEstimates_zltD6ZesgFXk" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Use of Estimates</b></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal In Year Four LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour	0	usd
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal In Year Five LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFive	0	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	773279	usd
CY2022	WDDD	Assets Range Useful Lives AssetsRangeUsefulLives	three to five years
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements EffectiveIncomeTaxRateReconciliationTaxSettlements	0.50	pure
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	773279	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	773279	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	22400000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11720000	shares
CY2001Q2	us-gaap	Litigation Reserve Noncurrent LitigationReserveNoncurrent	205000	usd
CY2021Q4	us-gaap	Litigation Reserve LitigationReserve	205000	usd
CY2022Q1	us-gaap	Legal Fees LegalFees	17780	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	124230	usd
CY2022Q4	WDDD	Convertible Notes Payable1 ConvertibleNotesPayable1	649049	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	773279	usd
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations Repayments Of Principal In Next Twelve Months LongTermDebtAndCapitalLeaseObligationsRepaymentsOfPrincipalInNextTwelveMonths	773279	usd
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal In Year Two LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo	0	usd
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal In Year Three LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree	0	usd
CY2022	us-gaap	Derivatives Embedded Derivatives DerivativesEmbeddedDerivatives	<p id="xdx_842_eus-gaap--DerivativesEmbeddedDerivatives_zWIGy4EgWyJ5" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Embedded Conversion Features</b></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluates embedded conversion features within convertible debt under ASC 815 “Derivatives and Hedging” to determine whether the embedded conversion feature(s) should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in earnings. If the conversion feature does not require derivative treatment under ASC 815, the instrument is evaluated under ASC 470-20 “Debt with Conversion and Other Options” for consideration of any beneficial conversion feature. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p>
CY2022	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<p id="xdx_846_eus-gaap--DerivativesReportingOfDerivativeActivity_zAERPGXLs0ei" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Derivative Financial Instruments</b></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income.</p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For option-based simple derivative financial instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
CY2022	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	75883	usd
CY2022	WDDD	Stock Split Terms StockSplitTerms	All common stock numbers and exercise prices in this Note are reflected on a post reverse split (5 to 1) basis. As a result of the reverse split on February 9, 2018
CY2018Q1	us-gaap	Stock Issued During Period Shares Stock Splits StockIssuedDuringPeriodSharesStockSplits	167	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod	15900000	shares
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	300000	shares
CY2022	WDDD	Stock Option Plan Expense1 StockOptionPlanExpense1	31807	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0137	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.42	pure
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.05
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased	0.05
CY2022	WDDD	Directors Options Expected Life DirectorsOptionsExpectedLife	P5Y
CY2022Q1	WDDD	Options Repriced OptionsRepriced	900000	shares
CY2021	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	297673	shares
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	70810	usd
CY2021	WDDD	Loss On Shares Issued LossOnSharesIssued	8685	usd
CY2021	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	109874	usd
CY2022	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	821995	usd
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	25800000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	25800000	shares
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	45000000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	17317788	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17317788	usd
CY2022	us-gaap	Valuation Allowance For Impairment Of Recognized Servicing Assets Period Increase Decrease ValuationAllowanceForImpairmentOfRecognizedServicingAssetsPeriodIncreaseDecrease	198580	usd
CY2021	us-gaap	Valuation Allowance For Impairment Of Recognized Servicing Assets Period Increase Decrease ValuationAllowanceForImpairmentOfRecognizedServicingAssetsPeriodIncreaseDecrease	161009	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	17317788	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	17292188	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17317788	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17292188	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.05	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.05	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.26	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.26	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0.21	pure
CY2018Q3	WDDD	Terms Of Employment Agreement TermsOfEmploymentAgreement	5
CY2018Q3	WDDD	Terms Of Employment Agreement Renewal Option TermsOfEmploymentAgreementRenewalOption	1
CY2018Q3	WDDD	Officer Base Salary OfficerBaseSalary	200000	usd
CY2018Q3	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease	0.10	pure
CY2018Q3	WDDD	Car Allowance CarAllowance	500	usd
CY2018Q3	WDDD	Annua Bonus AnnuaBonus	0.025	pure
CY2018Q3	WDDD	Additional Bonus AdditionalBonus	75000	usd
CY2018Q3	WDDD	Pretax Income Range Lower PretaxIncomeRangeLower	1.50	pure
CY2018Q3	WDDD	Pretax Income Range Higher PretaxIncomeRangeHigher	2	pure
CY2018Q3	WDDD	Additional Bonus Exceed AdditionalBonusExceed	0.05	pure
CY2018Q3	us-gaap	Life Settlement Contracts Investment Method Five Year Disclosure Premiums To Be Paid LifeSettlementContractsInvestmentMethodFiveYearDisclosurePremiumsToBePaid	10000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Maximum Number Of Shares Per Employee ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee	5000000	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.25
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	2000000	shares
CY2019Q3	WDDD	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber1	1500000	shares
CY2020Q3	WDDD	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber1	1500000	shares
CY2018Q3	us-gaap	Life Settlement Contracts Fair Value Method Face Value LifeSettlementContractsFairValueMethodFaceValue	2000000	usd
CY2018Q3	WDDD	Payment Amount Based PaymentAmountBased	2.99	pure
CY2018Q3	WDDD	Restrictive Convenants Amount RestrictiveConvenantsAmount	12	interger
CY2022Q1	us-gaap	Legal Fees LegalFees	17780	usd
CY2021	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	297673	shares
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	70810	usd
CY2021	WDDD	Loss On Shares Issued LossOnSharesIssued	8685	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	16401	usd
CY2021	us-gaap	Repayment Of Notes Receivable From Related Parties RepaymentOfNotesReceivableFromRelatedParties	9000	usd
CY2022	us-gaap	Repayment Of Notes Receivable From Related Parties RepaymentOfNotesReceivableFromRelatedParties	0	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Fair Value Disclosure AccountsPayableAndAccruedLiabilitiesFairValueDisclosure	53688	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Fair Value Disclosure AccountsPayableAndAccruedLiabilitiesFairValueDisclosure	33899	usd
CY2022	us-gaap	Revenue Recognition Services Licensing Fees RevenueRecognitionServicesLicensingFees	<p id="xdx_80C_eus-gaap--RevenueRecognitionServicesLicensingFees_zfq1ukM03z6i" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 8 - <span id="xdx_829_zcgsv3dSFKS7">PATENTS</span></b></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Worlds Inc. currently has <span id="xdx_909_ecustom--NumberOfPatents_dc_uInterger_c20220101__20221231_zGo8BzHnXBf2" title="Current patents">nine</span> patents, <span id="xdx_90F_ecustom--PatentNumberOne_uInterger_c20220101__20221231_z7L8k88qbjN8" title="Patent number one">6,219,045</span> - <span id="xdx_909_ecustom--PatentNumberTwo_uInterger_c20220101__20221231_zByIQx08xPCe" title="Patent number two">7,181,690</span> - <span id="xdx_90C_ecustom--PatentNumberThree_uInterger_c20220101__20221231_zOMcEAs3VnFl" title="Patent number three">7,493,558</span> – <span id="xdx_90E_ecustom--PatentNumberFour_uInterger_c20220101__20221231_z8SIIPH5Mk56" title="Patent number four">7,945,856</span>, - <span id="xdx_90E_ecustom--PatentNumberFive_uInterger_c20220101__20221231_ztunt1m5AsDl" title="Patent number five">8,082,501</span>, – <span id="xdx_905_ecustom--PatentNumberSix_uInterger_c20220101__20221231_zx5liHySoi6a" title="Patent number six">8,145,998</span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">– <span id="xdx_907_ecustom--PatentNumberSeven_uInterger_c20220101__20221231_z5O0Gjf5745i" title="Patent number seven">8,161,383</span>, – <span id="xdx_908_ecustom--PatentNumberEight_uInterger_c20220101__20221231_zk2oRZKnU4j1" title="Patent number eight">8,407,592</span> and <span id="xdx_902_ecustom--PatentNumberNine_uInterger_c20220101__20221231_zKeUA5r5Ifg4" title="Patent number nine"><span style="-sec-ix-hidden: xdx2ixbrl0675">8,640,028. </span></span>All of the patents have expired.</p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">See Legal Proceedings section for more information on the patent infringement lawsuits.</p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p>
CY2022	WDDD	Number Of Patents NumberOfPatents	9	interger
CY2022	WDDD	Patent Number One PatentNumberOne	6219045	interger
CY2022	WDDD	Patent Number Two PatentNumberTwo	7181690	interger
CY2022	WDDD	Patent Number Three PatentNumberThree	7493558	interger
CY2022	WDDD	Patent Number Four PatentNumberFour	7945856	interger
CY2022	WDDD	Patent Number Five PatentNumberFive	8082501	interger
CY2022	WDDD	Patent Number Six PatentNumberSix	8145998	interger
CY2022	WDDD	Patent Number Seven PatentNumberSeven	8161383	interger
CY2022	WDDD	Patent Number Eight PatentNumberEight	8407592	interger
CY2011Q1	WDDD	Retained Shares RetainedShares	5936115	shares
CY2022	WDDD	Realized Gain Loss On Marketable Securities Cost Method Investments And Other Investments1 RealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments1	793391	usd
CY2022	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	1200000	shares
CY2022Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.66
CY2021	WDDD	Realized Gain Loss On Marketable Securities Cost Method Investments And Other Investments1 RealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments1	1006588	usd
CY2021	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	1245000	shares
CY2020	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	100000	shares
CY2021Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.79
CY2022Q4	WDDD	Retained Shares Own RetainedSharesOwn	550000	shares
CY2022	WDDD	Retained Shares Own Value RetainedSharesOwnValue	0	usd
CY2001Q2	WDDD	Accounts Payable And Accrued Liabilities Fair Value Disclosur1e AccountsPayableAndAccruedLiabilitiesFairValueDisclosur1e	53688	usd
CY2001Q2	us-gaap	Litigation Reserve Noncurrent LitigationReserveNoncurrent	205000	usd
CY2022Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	1305009	usd
CY2022Q1	us-gaap	Legal Fees LegalFees	17780	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	3572	usd
CY2022	WDDD	Convertible Note Receivable Related Party ConvertibleNoteReceivableRelatedParty	<p id="xdx_808_ecustom--ConvertibleNoteReceivableRelatedParty_zd4LgUOHjIRl" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 11 – <span id="xdx_820_zYkM9ZAugpK5">CONVERTIBLE NOTE RECEIVABLE – RELATED PARTY</span></b></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company made an investment in the form of a convertible note in the amount of $<span id="xdx_900_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221231_zMOlceHPXIlg" title="Convertible note amount">200,000</span> to Canadian American Standard Hemp (CASH). The convertible note has a <span id="xdx_90B_eus-gaap--InvestmentInterestRate_iI_c20221231_zpHKAagbaKWc" title="Convertible note interest rate">7% </span>annual interest rate and matures in <span id="xdx_908_ecustom--MaturityTerms_uYears_c20220101__20221231_zz2YD3YFzYw" title="Convertible note maturity">2</span> years. Interest and principle is payable at maturity. The note can be converted at any time, either all or part of the amount due can be converted into the borrower’s equity. During the year ended December 31, 2020, CASH merged with Real Brands, Inc. The note was amended with a new maturity date of October 15, 2023. All other terms remained the same. As consideration for the extension, the Company received <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_dc_c20221231_zXe6NBn0o1De" title="Warrants for extension on note">one </span>million warrants to purchase Real Brands, Inc. common stock at <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231_zEiurMu4pco" title="Price per share">$0.05 </span>per share. The convertible note and accrued interest of <span id="xdx_90E_eus-gaap--InterestReceivableNoncurrent_iI_c20221231_zeCiy2L4WVEd" title="Convertible note and interest converted">$31,461 </span>can be converted into <span id="xdx_905_eus-gaap--ConversionOfStockSharesConverted1_c20220101__20221231_z1rnHB0fkZah" title="Number of shares per conversion">28,438,561 </span>shares of Real Brands common stock at a conversion price of <span id="xdx_902_eus-gaap--CommonStockConvertibleConversionPriceDecrease_c20220101__20221231_zTbiNeDEn1T5" title="Conversion price per share note conversion">$0.008139</span>. If converted into common stock, the Company would own approximately <span id="xdx_90D_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_c20221231_zDCcoewacitc">1% </span>of Real Brands Inc. Messrs. Kidrin, Toboroff and Christos are Directors of Real Brands and Mr. Kidrin is the CEO and Mr. Ryan is the CFO of Real Brands.<b> </b>Due to doubts about the collectability and the declining stock price of Real Brands Inc., the Company elected to impair the asset and recognize a loss on impairment of <span id="xdx_90F_eus-gaap--CertainLoansAcquiredInTransferAccountedForAsDebtSecuritiesOtherthanTemporaryImpairmentChargesCreditLoss_c20220101__20221231_zrd1yBmAkaNa" title="Loss on impairment">$231,462</span>.</p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p>
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	200000	usd
CY2022Q4	us-gaap	Investment Interest Rate InvestmentInterestRate	0.07	pure
CY2022	WDDD	Maturity Terms MaturityTerms	2
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.05
CY2022Q4	us-gaap	Interest Receivable Noncurrent InterestReceivableNoncurrent	31461	usd
CY2022	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	28438561	shares
CY2022	us-gaap	Common Stock Convertible Conversion Price Decrease CommonStockConvertibleConversionPriceDecrease	0.008139
CY2022Q4	us-gaap	Minority Interest Ownership Percentage By Noncontrolling Owners MinorityInterestOwnershipPercentageByNoncontrollingOwners	0.01	pure
CY2022	us-gaap	Certain Loans Acquired In Transfer Accounted For As Debt Securities Otherthan Temporary Impairment Charges Credit Loss CertainLoansAcquiredInTransferAccountedForAsDebtSecuritiesOtherthanTemporaryImpairmentChargesCreditLoss	231462	usd
CY2022	us-gaap	Nondebtor Reorganization Items Legal And Advisory Professional Fees NondebtorReorganizationItemsLegalAndAdvisoryProfessionalFees	8222	usd

Files In Submission

Name	View Source	Status
wddd-20221231_cal.xml	Edgar Link	unprocessable
0001264931-23-000006-index-headers.html	Edgar Link	pending
0001264931-23-000006-index.html	Edgar Link	pending
0001264931-23-000006.txt	Edgar Link	pending
0001264931-23-000006-xbrl.zip	Edgar Link	pending
ex31_1.htm	Edgar Link	pending
ex31_2.htm	Edgar Link	pending
ex32_1.htm	Edgar Link	pending
ex32_2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending
wddd-20221231.xsd	Edgar Link	pending
wdddk22.htm	Edgar Link	pending
wddd-20221231_def.xml	Edgar Link	unprocessable
wddd-20221231_pre.xml	Edgar Link	unprocessable
wddd-20221231_lab.xml	Edgar Link	unprocessable
wdddk22_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$WDDD
Worlds Inc Stock $wddd

2023 Q1 Form 10-K Financial Statement

#000126493123000006 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$WDDD Worlds Inc Stock $wddd

2023 Q1 Form 10-K Financial Statement

#000126493123000006 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$WDDD
Worlds Inc Stock $wddd